U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552233) titled 'NK Cell Therapy for Malignant Solid Brain Tumors' on April 20.
Brief Summary: This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as ...